<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03943199</url>
  </required_header>
  <id_info>
    <org_study_id>CRM-Alacran-2019</org_study_id>
    <nct_id>NCT03943199</nct_id>
  </id_info>
  <brief_title>Comparison of Lysine Clonixinate, Ketorolac and Metamizole Sodium in Scorpion Stings</brief_title>
  <official_title>Randomized Clinical Trial: Comparison of Lysine Clonixinate, Ketorolac and Metamizole Sodium in Poisoning by Scorpion Stings</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Mexican Red Cross</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Instituto Bioclon S.A. de C.V.</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Mexican Red Cross</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      The cases of scorpion stings are matters of medical importance, where Mexico is considered as
      one of the main countries of such public health problem.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The states with the highest incidence of cases in 2018 were Jalisco with 47370 bite reports,
      Guerrero with 40672 cases and Guanajuato with 40331, according to the national
      epidemiological surveillance system.

      Due to the high affinity on ion channels, where a cystine inhibitor BmP01, it is directed to
      the nociceptive ion channel TRPV1 to produce pain.Pain has been reported to occur in
      approximately 97% of patients They are seen in the emergency room.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">May 5, 2019</start_date>
  <completion_date type="Actual">July 20, 2019</completion_date>
  <primary_completion_date type="Actual">July 5, 2019</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Sequential Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Care Provider, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Evaluate the efficacy of antivenom as a pain treatment by the visual analogue scale of pain in poisoning by scorpion stings.</measure>
    <time_frame>18 hours after drugs in study</time_frame>
    <description>Comparison of venom metabolism in patients valued at 18 hours with Visual Analog Scales (VAS) valued from 0 to 10</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Evaluate the analgesic efficacy of clonixinate of lysine, ketorolac and sodium metamizol, by the visual analogue scale of pain in poisoning by scorpion stings.</measure>
    <time_frame>0, 30, 60 and 90 minutes after administered the drug</time_frame>
    <description>Comparison of the effectiveness inter group over the pain by scorpion sting by Visual Analog Scales (VAS) valued from 0 to 10</description>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Actual">160</enrollment>
  <condition>Scorpion Stings</condition>
  <condition>Pain</condition>
  <condition>Analgesic</condition>
  <arm_group>
    <arm_group_label>Metamizole sodium</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>1 gram intravenous, will be diluted in 0.9% physiological solution of 100 ml, applied for 30 minutes</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Ketorolac</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>60 milligrams intravenously, it will be added to 20 ml with 0.9% physiological solution, it will be applied for 5 minutes</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Lysine Clonixinate</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>100 milligram intravenously, diluted in 5% glucose solution of 100 ml, applied for 30 minutes</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>20 milliliters of 0.9% physiological solution, will be applied for 5 minutes.</description>
  </arm_group>
  <intervention>
    <intervention_type>Diagnostic Test</intervention_type>
    <intervention_name>Visual Analogue Scale for pain</intervention_name>
    <description>Will be assessed at 0´, 30´, 60´, 90 minutes and 18 hours after the application of the analgesic.</description>
    <arm_group_label>Ketorolac</arm_group_label>
    <arm_group_label>Lysine Clonixinate</arm_group_label>
    <arm_group_label>Metamizole sodium</arm_group_label>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Clinical diagnosis of pain by scorpion stings

          -  Patients&gt; 18 years old

          -  Clinical diagnosis of scorpion sting poisoning grade I, II and III.

          -  Chronic degenerative diseases (renal failure, hypertension, liver damage)

        Exclusion Criteria:

          -  Patients who reject the continuation of medical treatment

          -  Patients who are transferred to a unit of second level of care.

          -  Patients with pharmacological treatment prior
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Alfredo Luis H Chávez Haro</last_name>
    <role>Study Director</role>
    <affiliation>Investigator</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Josue Saul H Almaraz</last_name>
    <role>Principal Investigator</role>
    <affiliation>Investigator</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Cruz Roja Mexicana, Delegación León</name>
      <address>
        <city>León</city>
        <state>Guanajuato</state>
        <zip>37179</zip>
        <country>Mexico</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Mexico</country>
  </location_countries>
  <verification_date>July 2019</verification_date>
  <study_first_submitted>May 6, 2019</study_first_submitted>
  <study_first_submitted_qc>May 7, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">May 9, 2019</study_first_posted>
  <last_update_submitted>July 29, 2019</last_update_submitted>
  <last_update_submitted_qc>July 29, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">July 30, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Mexican Red Cross</investigator_affiliation>
    <investigator_full_name>Josue Saul Almaraz Lira</investigator_full_name>
    <investigator_title>Principal Investigator</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Bites and Stings</mesh_term>
    <mesh_term>Scorpion Stings</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

